The Senior Care Pharmacist

MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?

The Senior Care Pharmacist July 31, 2024 Leigh Davitian 1 citation

In recent years, scientists have initiated a renaissance in psychedelic research following decades of prohibition. Compounds such as ketamine, LSD, and psilocybin 'once primarily associated with recreational use' are now being investigated for their therapeutic potential, with promising results. An estimated 40-60% of people with post-traumatic stress disorder (PTSD) do not respond to selective...